Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Previous Page

Next Page

Page Background

ALK

patients: outstanding OS with 1

st

G

EAP CLINALK

•

N=318

•

Crizo

à

next gen.

TKIs.

•

OS = 7,5 years

89.6 months

28.2 months

19.6 months

Crizo.

à

Next Gen.

Crizo.

à

Chemo

BSC

Duruisseaux - Oncotarget 2017 (Courtesy of Prof. Bess)